Patents Issued in September 30, 2014
  • Patent number: 8846596
    Abstract: Liquid cleaning compositions are described herein that include a metal bleach catalyst which is a complex of a transition-metal and a macrocyclic ligand, the ligand having a calculated Octanol/Water Partition Coefficient value of from about ?1.50 to about ?0.10, a formulation enabling fraction comprising at least one formulation enabling ingredient, the formulation enabling fraction having a Hydrophilic Index of from about 4.0 to about 10.0, and a formulation deactivating fraction comprising at least one formulation deactivating ingredient that has a calculated Octanol/Water Partition Coefficient value of from about ?3.5 to about ?0.10.
    Type: Grant
    Filed: February 16, 2012
    Date of Patent: September 30, 2014
    Assignee: The Procter & Gamble Company
    Inventors: Robert Richard Dykstra, Mario Elmen Tremblay, Xiaoru Jenny Wang, James Lee Danziger, Daniel Dale Ditullio, Jr., Consuelo Kong, Ismael Cotte-Rodriguez
  • Patent number: 8846597
    Abstract: Methodologies and equipment for using a hypochlorite solution to remove menstrual fluid, underarm perspiration or other hard-to-remove stains from soft fabric articles with reduced damage to the fabric articles when compared with popular chlorine bleaches. The soft fabric articles preferably are in white, although the present invention can also be applied to articles in other colors. In one embodiment, the weight concentration ratio of the alkali metal hydroxide over the hypochlorite salt in the hypochlorite solution is no less than 1:12.5. The hypochlorite solution may contain at least 0.2% by weight of sodium hydroxide and/or have a pH of at least 11.8.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: September 30, 2014
    Assignee: LH Taylor Associates
    Inventor: Lawnie Henderson Taylor
  • Patent number: 8846598
    Abstract: The present invention relates to a composition comprising: (i) a bacterial alkaline enzyme exhibiting endo-beta-1,4-glucanase activity (E.C. 3.2.1.4); and (ii) a bleach catalyst that is capable of accepting an oxygen atom from a peroxyacid and transferring the oxygen atom to an oxidizeable substrate.
    Type: Grant
    Filed: July 9, 2007
    Date of Patent: September 30, 2014
    Assignee: The Procter & Gamble Company
    Inventors: Neil Joseph Lant, Gregory Scot Miracle, Philip Frank Souter
  • Patent number: 8846599
    Abstract: Branched polyesters with sulfonate groups obtainable by the reaction of the components A, B, optionally C and optionally D to give branched polyesters, where the component A is selected from the group of ?,?-olefinically unsaturated dicarboxylic acids, and the component B is selected from the group of tri- or higher-functional alcohols, the optional component C is selected from the group of difunctional alcohols or of difunctional carboxylic acids without ?,?-olefinically unsaturated bonds, the optional component D is selected from fatty acids or fatty alcohols, and the subsequent reaction of the resulting branched polyesters with hydrogen sulfite, where the molar amount of hydrogen sulfite is at most 95 mol %, based on the amount of ?,?-olefinically unsaturated dicarboxylic acid.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: September 30, 2014
    Assignee: BASF SE
    Inventors: Monika Haberecht, Frank Rittig, Bernd Bruchmann, Claudia Esper, Roland Ettl, Karl Kolter
  • Patent number: 8846600
    Abstract: Disclosed are carboxamide compounds as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure in which R1, R2, R3, R4, T, p, q, w and x are as described herein. In certain embodiments, a compound disclosed herein activates the AMPK pathway, and can be used to treat metabolism-related disorders and conditions.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: September 30, 2014
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Ihab S. Darwish, Hui Hong, Rajinder Singh, Xiang Xu
  • Patent number: 8846601
    Abstract: Melanocortin receptor-specific cyclic peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and z are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: September 30, 2014
    Assignee: Palatin Technologies, Inc.
    Inventors: Yi-qun Shi, Shubh D. Sharma, John H. Dodd, Wei Yang, Xin Chen
  • Patent number: 8846602
    Abstract: The invention relates to a method for producing injectable medicament preparations containing a therapeutically and/or diagnostically effective substance which is comprised of an active agent, of a spacer molecule and of at least one protein-binding molecule. After being brought into contact with the body, said therapeutically and/or diagnostically effective substance covalently bonds to the body fluid constituents or tissue constituents via the protein-binding molecule, thus providing a form of transport of the active agent that an be hydrolytically or enzymatically cleaved, according to pH, in the body while releasing the active agent.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: September 30, 2014
    Assignee: KTB Tumorforschungs GmbH
    Inventor: Felix Kratz
  • Patent number: 8846603
    Abstract: The present invention provides a novel fusion polypeptide containing a catalytic portion of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: September 30, 2014
    Assignee: Synageva Biopharma Corp.
    Inventors: Anthony Quinn, Alex J. Harvey, Zhinan Xia
  • Patent number: 8846604
    Abstract: The invention provides lipid compositions comprising phospholipids having a high docosahexaenoic acid (DHA) content, which compositions are preferably extracted from natural sources. The lipid compositions are excellent sources of highly bioavailable DHA and they can be used in oral delivery vehicles, dietary supplements, functional foods, and the like.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: September 30, 2014
    Assignee: Artic Nutrition AS
    Inventors: Hogne Hallaraker, Jan Remmereit, Alvin Berger
  • Patent number: 8846605
    Abstract: This invention relates to a topical gel drug product preparation containing a composition comprising an isolated polypeptide having a carboxy-terminal amino acid sequence of an alpha connexin (ACT peptide), peptide stabilizers, excipients, buffering agents, and the like. A formulation and preparation steps are disclosed for the manufacturing of a stable, elegant, and pourable topical gel. The resulting formulation possesses long term stability suitable for aesthetic as well as therapeutic applications including the prevention of scaring and accelerated healing of wounds. Methods for treatment of chronic wounds, including chronic ulcers, are also provided.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 30, 2014
    Assignee: Firstring Research, Inc.
    Inventor: Gautam Ghatnekar
  • Patent number: 8846606
    Abstract: Provided herein are methods and compositions for treating septic hypotension. More specifically, the methods may comprise, administering one alpha-2 agonist or other sympatholytic and at least one vasopressor.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: September 30, 2014
    Inventor: Luc Quintin
  • Patent number: 8846607
    Abstract: Formulations have been developed to treat or reduce the spread of respiratory infections, especially chronic or drug resistant infections, particularly tuberculosis (TB), severe acute respiratory syndrome (SARS), meningococcal meningitis, Respiratory syncytial virus (RSV), influenza, and small pox. Formulations include a drug or vaccine in the form of a microparticle, nanoparticle, or aggregate of nanoparticles, and, optionally, a carrier, which can be delivered by inhalation. Giving the drugs via an inhaler sidesteps the problems associated with oral or injectable drugs by bypassing the stomach and liver, and delivering the medication directly into the lungs. In one embodiment, the particle containing the agent is a large porous aerosol particle (LPPs). In another embodiment, the particles are nanoparticles, which can be administered as porous nanoparticle aggregates with micron diameters that disperse into nanoparticles following administration.
    Type: Grant
    Filed: October 19, 2005
    Date of Patent: September 30, 2014
    Assignee: President and Fellows of Harvard College
    Inventors: David A. Edwards, Jennifer Fiegel, Jean Sung
  • Patent number: 8846608
    Abstract: The present invention relates to new peptides and to use thereof, in particular for treatment and/or prevention of infections, inflammations, pain, wounds, scar and/or tumors.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: September 30, 2014
    Assignee: Pergamum AB
    Inventors: Margit Mahlapuu, Camilla Björn, Veronika Sjöstrand, Björn Walse, Bo Svenson
  • Patent number: 8846609
    Abstract: The present invention relates to methods for preventing or treating Human Immunodeficiency Virus (HIV) infection, inflammatory conditions, and graft-versus-host-disease (GVHD) in a subject. Therapeutic compositions of the present invention comprise Leukocidin E (LukE) and/or D proteins or polypeptides. The invention further relates to methods of treating Staphylococcus aureus infection by administering a composition comprising a CCR5 antagonist or any molecule that blocks LukE/D interaction with CCR5+ cells in an amount effective to treat the S. aureus infection in the subject.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: September 30, 2014
    Assignee: New York University
    Inventors: Victor J. Torres, Derya Unutmaz, Francis Alonzo, III
  • Patent number: 8846610
    Abstract: The present invention relates to crystalline and crystal-like forms of lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention relates to methods of purifying lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention also relates to pharmaceutical compositions comprising the purified form of the lipopeptide and methods of using these compositions.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: September 30, 2014
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: Dennis Keith, Jan-Ji Lai, Chandrika Govardhan, Nazer Khalaf
  • Patent number: 8846611
    Abstract: Disclosed herein is a skin condition-improving composition for topical application to the skin, comprising human growth hormone as an active ingredient, and a method for improving skin conditions using the same. The disclosed composition exhibits various skin conditioning effects, such as acne treatment, wrinkle improvement, dark spot removal, skin elasticity improvement, hair growth stimulation, skin aging prevention, skin moisturization and the proliferation of skin epidermal stem cells.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: September 30, 2014
    Assignee: Regeron, Inc.
    Inventors: Dahl Kyun Oh, Sang Jung Baik, Kyung Young Lee
  • Patent number: 8846612
    Abstract: The use of a protein source comprising bovine casein proteins for the preparation of a nutrional composition for administration to an infant, young child or adult during or after a period of catch-up growth or weight recovery, following a period of growth restriction or weight lost, so as improve growth at early age and/or to reduce the risk of development of insulin resistance and/or Type 2 diabetes later in the life of the infant, young child or adult.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: September 30, 2014
    Assignee: Nestec S.A.
    Inventors: Olivier Aprikian, Florence Blancher, Catherine Mace, Yassaman Shahkhalili
  • Patent number: 8846613
    Abstract: The invention relates to a pharmaceutical composition comprising 1.a and/or 1.b according to claim 1 in combination with at least one second therapeutic agent 2 which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: September 30, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Bradford S. Hamilton, Thomas Rauch, Manami Tsutsumi
  • Patent number: 8846614
    Abstract: A process for the production of pramlintide, a 37-mer peptide, is provided. The synthesis provides a high yield synthesis of the peptide in relatively pure form. Further purification can be achieved by preparative HPLC.
    Type: Grant
    Filed: August 22, 2012
    Date of Patent: September 30, 2014
    Assignee: USV Limited
    Inventors: Nikhil Umesh Mohe, Praful Shamrao Chavre, Bharti Prabhakarrao Deshmukh, Chandrakesan Muralidharan, Lester John Lobo, Digamber Shripati Pawar, Divya Lal Saksena
  • Patent number: 8846615
    Abstract: The present invention relates to novel Motoneuronotrophic Factors (MNTF) peptides and analogs thereof, including compositions capable of promoting the growth and viability of neurons. MNTF peptides between two and six amino acids in length are provided, as well as analogs of these MNTF peptides that are modified by covalent attachment to another moiety. Other embodiments are described herein.
    Type: Grant
    Filed: February 23, 2009
    Date of Patent: September 30, 2014
    Assignee: Genervon Biopharmaceuticals, LLC
    Inventors: Pui-Yuk Dorothy Ko, Mark S. Kindy
  • Patent number: 8846616
    Abstract: A method is presented for treating an inflammatory skin disorder in a human comprising: topically applying to the skin a composition comprising alpha-melanocyte stimulating hormone (?MSH) or an ?MSH analog in an amount effective to reduce skin inflammation in the human.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: September 30, 2014
    Assignees: Florida Agricultural and Mechanical University, The Board of Trustees at the University of Arkansas
    Inventors: Mandip Singh Sachdeva, Cheryl Armstrong, Melissa A. Brown
  • Patent number: 8846617
    Abstract: The present invention relates to the use of compounds selected from the group consisting of Lys-(D)Pro-Thr, N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr; or a pharmaceutically acceptable salt of said compound fort he treatment of inflammatory disorders. The invention also relates to the use of ?MSH for inducing tolerance.
    Type: Grant
    Filed: July 16, 2011
    Date of Patent: September 30, 2014
    Inventor: Thomas Luger
  • Patent number: 8846618
    Abstract: Pharmaceutical formulations of GLP-1 compounds and methods for preparation thereof.
    Type: Grant
    Filed: May 24, 2010
    Date of Patent: September 30, 2014
    Assignee: Novo Nordisk A/S
    Inventors: James M. Flink, Silke Møller Larsen, Simon Bjerregaard Jensen, Dorthe Kot Engelund
  • Patent number: 8846619
    Abstract: This invention provides heme-containing peptides capable of binding molecular oxygen at room temperature. These compounds may be useful in the absorption of molecular oxygen from molecular oxygen-containing atmospheres. Also included in the invention are methods for treating an oxygen transport deficiency in a mammal.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: September 30, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: P. Leslie Dutton
  • Patent number: 8846620
    Abstract: Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) in combination with a gastrointestinal epithelial barrier permeation enhancer is orally administered to a subject in a manner sufficient to enhance blood coagulation in the subject. Compositions and kits for practicing methods of the invention are also described.
    Type: Grant
    Filed: July 18, 2012
    Date of Patent: September 30, 2014
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Peter Turecek, Susanne Vejda
  • Patent number: 8846621
    Abstract: Pharmaceutical compositions and methods for treating diseases associated with angiogenesis and inflammation. The invention relates to a pharmaceutical composition that includes a therapeutically effective amount of sCD26 and/or a biologically active derivative thereof and a pharmaceutically acceptable carrier. The composition may further include a therapeutically effective amount of sFlt-1 and/or a biologically active derivative thereof. Additionally, the invention relates to methods for treating a disease associated with and/or progresses by an inflammatory cytokine-associated inflammation and/or VEGF-associated angiogenesis.
    Type: Grant
    Filed: December 1, 2009
    Date of Patent: September 30, 2014
    Inventor: Chiwen Chang
  • Patent number: 8846622
    Abstract: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the sphenopalatine ganglion. Exemplary delivery is carried out by way of injection.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: September 30, 2014
    Assignee: Allergan, Inc.
    Inventor: Andrew M. Blumenfeld
  • Patent number: 8846623
    Abstract: Cancer-targeting peptides having a PX1LX2 motif, in which X1 is His or an amino acid residue with a hydrophobic side chain and X2 is Pro, Phe, or Trp. Also disclosed herein are conjugates containing the cancer-targeting peptides and uses thereof in cancer treatment and diagnosis.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: September 30, 2014
    Assignee: Academia Sinica
    Inventors: John Yu, Alice L. Yu, H. C. Wu, Sheng-Hung Wang, I-Ju Chen
  • Patent number: 8846624
    Abstract: In an embodiment, a number of synthetic protein triblock copolymers are provided comprising first and second end hydrophobic blocks separated by a central hydrophilic block. In particular, the synthetic proteins are elastin-mimetic proteins having improved mechanical characteristics and related methods of making the proteins with the capability of providing precise control over the mechanical properties. Provided are proteins used in a number of medical devices such as artificial blood vessels, shunts, stents or as embolic agents in situations where it is desired to stop or reduce blood flow or pressure in a localized region.
    Type: Grant
    Filed: September 11, 2007
    Date of Patent: September 30, 2014
    Assignee: Emory University
    Inventors: Elliot L. Chaikof, Vincent P. Conticello
  • Patent number: 8846625
    Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: September 30, 2014
    Assignee: 1149336 Ontario Inc.
    Inventors: Daniel J Drucker, Anna E. Crivici, Martin Sumner-Smith
  • Patent number: 8846626
    Abstract: A drug composition for treating chronic liver diseases, consists of: Astragalus Astragalosides and Glycyrrhiza Acid by weight ratio of 3˜6:1. By testing and validating with classic animal model, the results confirmed that the drug composition of the present invention can significantly reduce the collagen content of rat liver, and reduce liver fibrosis and liver injury, wherein the effect is better than the effect of each component alone. The drug composition of the two components or ingredients can improve the anti-hepatic fibrosis, effectively prevent liver fibrosis and promote the development of liver fibrosis reversal, and thus can be used for the treatment and prevention of various chronic hepatitis, liver fibrosis, cirrhosis and other illnesses.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: September 30, 2014
    Assignee: Shuguang Hospital Affiliated with Shanghai University of Traditional Chinese Medicine
    Inventor: Ping Liu
  • Patent number: 8846627
    Abstract: A method for treatment of malaria including administering to a patient in need thereof a flavonoid glycoside compound.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: September 30, 2014
    Assignees: The Second Military Medical University, East China University of Science and Technology
    Inventors: Weidong Zhang, Jin Huang, Lei Shan, Honglin Li, Liyan Wang, Shoude Zhang, Weiqiang Lu, Juan Su, Tong Chen
  • Patent number: 8846628
    Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs, for example, 5-azacytidine or decitabine, for oral administration, wherein the compositions release the cytidine analog, for example, 5-azacytidine or decitabine, substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: September 30, 2014
    Assignee: Celgene Corporation
    Inventors: Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
  • Patent number: 8846629
    Abstract: A method for treatment and amelioration of breast, cervical, ovarian, endometrial, squamous cells, prostate cancer and melanoma in a patient comprising targeting Id-1 or Id-2 gene expression with a delivery vehicle comprising a product which modulates Id-1 or Id-2 expression.
    Type: Grant
    Filed: December 2, 2008
    Date of Patent: September 30, 2014
    Assignees: The Regents of the University of California, California Pacific Medical Center Research Institute
    Inventors: Pierre-Yves Desprez, Judith Campisi
  • Patent number: 8846630
    Abstract: The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.
    Type: Grant
    Filed: November 1, 2010
    Date of Patent: September 30, 2014
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Misun Won, Kyung-Sook Chung, Young Joo Kim, Hye Kyung Hong, Young Il Yeom, Chae Ok Yun, Yu-Kyoung Oh, Kyung Bin Song, Hee Gu Lee, Young Ho Kim, Moon Hee Kim, Kyeong-Eun Jung, Seok Hoon Song
  • Patent number: 8846631
    Abstract: Provided herein are compositions comprising oligomeric compounds. In certain embodiments, the oligomeric compounds are useful as miRNA mimics. The oligomeric compounds may mimic the activity of miR-34. Also provided herein are methods for the treatment of cancer.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: September 30, 2014
    Assignee: Regulus Therapeutics Inc.
    Inventors: Eric G. Marcusson, Balkrishen Bhat, Peter Linsley, Akin Akinc
  • Patent number: 8846632
    Abstract: Compositions and methods effective for modulating Hepatitis C viral infection are provided.
    Type: Grant
    Filed: September 4, 2012
    Date of Patent: September 30, 2014
    Assignee: The Children's Hospital of Philadelphia
    Inventor: Linda B. Couto
  • Patent number: 8846633
    Abstract: The present invention provides a method for inhibiting cancer stem cell like properties and chemoradioresistant properties of cancer or tumor cells comprising delivering miR145 to the cancer or tumor cells, particularly brain tumor and head and neck cancer cells. The invention further provides a pharmaceutical composition comprising miR145 and a method for treating brain tumor and/or head and neck cancer comprising administration of miR145 to a subject in need thereof.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: September 30, 2014
    Assignee: Taipei Veterans General Hospital
    Inventors: Shih-Hwa Chiou, Han-Shui Hsu, Jong-Yuh Cherng
  • Patent number: 8846635
    Abstract: The present application provides methods and compositions for inducing hepatocyte proliferation and liver regeneration, the latter being mainly dependent on hepatocyte proliferation even if all the other cell types divide to reconstitute the organ specific-lobular-architecture. The methods and compositions provided herein make use of an A3AR agonist. A preferred A3AR agonist disclosed herein is Cl-IB-MECA.
    Type: Grant
    Filed: October 22, 2008
    Date of Patent: September 30, 2014
    Assignee: Can-Fite Biopharma Ltd.
    Inventors: Pnina Fishman, Shira Cohen
  • Patent number: 8846636
    Abstract: The disclosure provides nucleotide analogues that comprise tetrahydrofuranyl or tetrahydrothienyl moieties with quaternary centers at the 3? position, the pharmaceutical formulations comprising the analogues, and methods of using the analogues and formulations for treating, preventing, and/or inhibiting diseases or conditions associated with cancers and viruses.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: September 30, 2014
    Assignee: LCB Pharma Inc.
    Inventor: Yvan Guindon
  • Patent number: 8846637
    Abstract: Provided herein are 2?-amino and 2?-thio bicyclic nucleosides and oligomenc compounds prepared therefrom. The novel bicyclic nucleosides provided herein are expected to be useful for enhancing one or more properties of the oligomeric compounds they are incorporated into such as nuclease resistance.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: September 30, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Thazha P. Prakash, Eric E. Swayze
  • Patent number: 8846638
    Abstract: The present invention provides nucleoside phosphoramidate compounds of Formula I, where R1, R2a, R2b, R3, R4, R5a, R5b, R6, R7, R8a, R8b, M and W are as defined herein. The invention further includes pharmaceutical compositions comprising a compound of Formula I, methods of use of these compounds for treating a viral infection, and methods of producing these compounds.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: September 30, 2014
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yat Sun Or, Jun Ma, Guoqiang Wang
  • Patent number: 8846639
    Abstract: In certain embodiments, the present invention provides oligomeric compounds having favorable toxicity profiles and therapeutic indexes. Compounds of the present invention comprise bicyclic nucleosides. Certain such bicyclic nucleosides are pyrimidines that do not include a methyl group at the 5-carbon. Oligomeric compounds comprising such nucleosides are less toxic than compounds comprising bicyclic nucleosides that do include a methyl group at the 5-carbon. In certain embodiments, the present invention provides methods of preparing and using such compounds.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: September 30, 2014
    Assignee: Isis Pharmaceutical, Inc.
    Inventors: Eric E. Swayze, Andrew M. Siwkowski
  • Patent number: 8846640
    Abstract: Biomaterials obtainable by mixing the autocrosslinked derivative of hyaluronic acid (ACP) with the derivative (HBC) of hyaluronic acid crosslinked with 1,4-butanediol diglycidyl ether (BDDE) in the weight ratio of between 10:90 and 90:10 as novel fillers.
    Type: Grant
    Filed: August 25, 2010
    Date of Patent: September 30, 2014
    Assignee: Fidia Farmaceutici S.p.A.
    Inventors: Matteo D'este, Davide Renier
  • Patent number: 8846641
    Abstract: The present invention relates to viscosity stabilized ophthalmic formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a diol alcohol such as sorbitol and, optionally, a pharmaceutically acceptable divalent cation salt such as magnesium chloride.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: September 30, 2014
    Assignee: Alcon Research, Ltd.
    Inventors: Howard Allen Ketelson, James W. Davis, David L. Meadows
  • Patent number: 8846642
    Abstract: A nutritional composition for administration to an infant which composition comprises, on a dry matter basis, from 2.5 to 15.0 wt % of an oligosaccharide mixture consisting of N-acetylated oligosaccharide(s), galacto-oligasaccharide(s) and sialylated oligosaccharide(s) with the proviso that the composition comprises at least 0.02 wt % of an N-acetylated oligosaccharide, at least 2.0 wt % of a galacto-oligosaccharide and at least 0.04 wt % of a sialylated oligosaccharide and that the N-acetylated oligosaccharide(s) comprise 0.5 to 4.0% of the oligosaccharide mixture, the galacto-oligosaccharide(s) comprise 92.0 to 98.5% of the oligosaccharide mixture and the sialylated oligosacchardide(s) comprise 1.0 to 4.0% of the oligosaccharide mixture. The composition is useful for administration to an infant in the first six months of life to reduce the risk of obesity later in life.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: September 30, 2014
    Assignee: Nestec S.A.
    Inventors: Marie-Claire Fichot, Norbert Sprenger, Francois-Pierre Martin, Sunil Kochhar, Serge Rezzi
  • Patent number: 8846643
    Abstract: There are provided, inter alia, acyclic nucleoside phosphonate compounds having reduced toxicity and enhanced antiviral activity, and pharmaceutically accepted salts and solvates thereof. There are also provided methods of using the disclosed compounds for inhibiting viral RNA-dependent RNA polymerase, inhibiting viral reverse transcriptase, inhibiting replication of virus, including hepatitis C virus or a human retrovirus, and treating a subject infected with a virus, including hepatitis C virus or a human retrovirus.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: September 30, 2014
    Assignee: The Regents of the University of California
    Inventors: Karl Y. Hostetler, James R. Beadle, Nadejda Valiaeva
  • Patent number: 8846644
    Abstract: A phosphate-containing nanoparticle delivery vehicle includes nanoparticle, an active ingredient, and a phosphodiester moiety connecting the nanoparticle and the active ingredient and forms a prodrug. The nanoparticle delivery vehicle achieves the function of increasing hydrophilicity of the active ingredient and specificity against tumor cells. Advantages of the nanoparticle material include biocompatibility, magnetism and/or controllable drug release.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: September 30, 2014
    Assignee: National Cheng-Kung University
    Inventors: Jih Ru Hwu, Yu-Sern Lin, Chen-Sheng Yeh, Dar-Bin Shieh, Wu-Chou Su
  • Patent number: 8846645
    Abstract: The present invention relates to compounds according to general formula (I), pharmaceutical compositions comprising compounds according to general formula (I) and the use of the compounds for the treatment of a bacterial infection, particularly for use as an antibiotic.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: September 30, 2014
    Assignees: Rheinische Friedrich-Wilhelms Universität Bonn, Universität Konstanz
    Inventors: Günter Mayer, Christina Elsbeth Luense, Valentin Wittmann, Magnus S. Schmidt
  • Patent number: 8846646
    Abstract: The invention relates to an unexpected discovery that propylene glycol is highly effective at killing or inhibiting Propionibacterium acnes in a mammalian skin disorder, as well as to the use of propylene glycol and salicylic acid in a skin-disorder treatment. This invention also relates to compositions containing propylene glycol alone or in combination with salicylic acid for use in killing or inhibiting Propionibacterium acnes.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: September 30, 2014
    Assignee: Winlind Skincare, LLC
    Inventor: Win L Chiou